Overview

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as ""second generation"" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Full Product Details

Author:   Brian W. Metcalf (Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.) ,  Susan Dillon (Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Dimensions:   Width: 18.40cm , Height: 2.40cm , Length: 26.00cm
Weight:   0.820kg
ISBN:  

9780123693938

ISBN 10:   0123693934
Pages:   296
Publication Date:   01 November 2006
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Out of Print
Availability:   In Print  
Limited stock is available. It will be ordered for you and shipped pending supplier's limited stock.

Table of Contents

I: Pharmaceutical biotechnology for target validation Chapter 1: GENERATION OF TRANSGENIC ANIMALS Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS II: Target validation for biopharmaceutical drug discovery Chapter 3: CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION III: Validating targets of small molecule approaches Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY INDEX

Reviews

Author Information

Tab Content 6

Author Website:  

Countries Available

All regions